SPORE in Prostate Cancer

描述（由申请人提供）：梅奥诊所综合癌症中心的前列腺癌研究卓越专业项目（SPORE）将支持一个由基础、临床和人口科学研究者组成的跨学科团队，进行旨在显著降低这种恶性肿瘤死亡率的转化研究。Donald J. Tindall博士将担任首席研究员，Brian J. Davis博士将担任联合首席研究员。SPORE的转化研究目标将由六个研究项目指导：项目1：血清和组织生物标志物的应用，用于预测前列腺特异性抗原（PSA）上升的男性人群在接受最终治疗后对雄激素缺乏治疗的反应（George G. Klee，医学博士），项目2：振动声成像前列腺（Mostafa Fatemi，博士），项目3：使用放射性碘进行前列腺癌基因治疗（John C. Morris， III，医学博士），项目4：一项随机II期临床试验，以确定同种异体全细胞疫苗加或不加自体髓系树突状细胞对雄激素非依赖性前列腺癌患者的安全性、耐受性和有效性（Stanimir Vuk-Pavlovic，博士），以及项目5：前列腺癌免疫治疗方法（Esteban Cells，医学博士，博士）。五个核心资源将支持这些研究项目：核心1：行政核心（Donald J. Tindall，博士），核心2：生物标本核心（John C. Cheville，医学博士），核心3：临床核心（Brian J. Davis，医学博士），核心4：生物统计学核心（Eric J. Bergstralh， M.S.），核心5：患者倡导者核心（Donald D. Layton, Jr.，医学博士）。已经建立了一个发展研究计划，以探索创新研究的机会，并组织了一个职业发展计划，以促进年轻研究人员在前列腺癌转化研究中建立独立。SPORE结构提供了一种理想的机制来集中和整合研究者的发现努力，并最佳地利用梅奥诊所的临床资源，继续在前列腺癌的治疗方面取得有意义的进展。

DESCRIPTION (provided by applicant): This Specialized Program of Research Excellence (SPORE) in prostate cancer at the Mayo Clinic Comprehensive Cancer Center will support an interdisciplinary team of basic, clinical, and population science investigators to perform translational research directed at significantly reducing mortality from this malignancy. Donald J. Tindall, Ph.D., will serve as the Principal Investigator and Brian J. Davis, M.D., Ph.D., will serve as Co-Principal Investigator. The translational research objectives of the SPORE will be directed by six research projects: Project 1: Utility of Serum and Tissue Biomarkers for Predicting Response to Androgen Deprivation Therapy in the Population of Men with Rising PSA Following Definitive Treatment (George G. Klee, M.D., Ph.D.), Project 2: Prostate Imaging by Vibro-acoustography (Mostafa Fatemi, Ph.D.), Project 3: Gene Therapy of Prostate Cancer Using Radioactive Iodine (John C. Morris, III, M.D.), Project 4: A Randomized Phase II Clinical Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With or Without Autologous Myeloid Dendritic Cells to Patients Suffering From Androgen Independent Prostate Carcinoma (Stanimir Vuk-Pavlovic, Ph.D.), and Project 5: An Immune-Based Therapeutic Approach for Prostate Cancer (Esteban Cells, M.D., Ph.D.). Five core resources will support these research projects: Core 1: Administrative Core (Donald J. Tindall, Ph.D.), Core 2: Biospecimens Core (John C. Cheville, M.D.), Core 3: Clinical Core (Brian J. Davis, M.D., Ph.D.), Core 4: Biostatistics Core (Eric J. Bergstralh, M.S.), and Core 5: Patient Advocate Core (Donald D. Layton, Jr., M.D.) A Developmental Research Program has been established to explore opportunities for innovative research and a Career Development Program has been organized to facilitate young investigators to establish independence in prostate cancer translational research. The SPORE structure provides the ideal mechanism to focus and integrate the discovery efforts of investigators and to optimally utilize the clinical resources of the Mayo Clinic practice to continue to make meaningful advances in the management of prostate cancer.